173 related articles for article (PubMed ID: 31464370)
1. CRISPR screens are feasible in TP53 wild-type cells.
Brown KR; Mair B; Soste M; Moffat J
Mol Syst Biol; 2019 Aug; 15(8):e8679. PubMed ID: 31464370
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9 treatment causes extended TP53-dependent cell cycle arrest in human cells.
Geisinger JM; Stearns T
Nucleic Acids Res; 2020 Sep; 48(16):9067-9081. PubMed ID: 32687165
[TBL] [Abstract][Full Text] [Related]
3. Parallel CRISPR-Cas9 screens clarify impacts of p53 on screen performance.
Bowden AR; Morales-Juarez DA; Sczaniecka-Clift M; Agudo MM; Lukashchuk N; Thomas JC; Jackson SP
Elife; 2020 May; 9():. PubMed ID: 32441252
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response.
Park DE; Cheng J; Berrios C; Montero J; Cortés-Cros M; Ferretti S; Arora R; Tillgren ML; Gokhale PC; DeCaprio JA
Proc Natl Acad Sci U S A; 2019 Jan; 116(3):1027-1032. PubMed ID: 30598450
[TBL] [Abstract][Full Text] [Related]
5. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response.
Haapaniemi E; Botla S; Persson J; Schmierer B; Taipale J
Nat Med; 2018 Jul; 24(7):927-930. PubMed ID: 29892067
[TBL] [Abstract][Full Text] [Related]
6. p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells.
Ihry RJ; Worringer KA; Salick MR; Frias E; Ho D; Theriault K; Kommineni S; Chen J; Sondey M; Ye C; Randhawa R; Kulkarni T; Yang Z; McAllister G; Russ C; Reece-Hoyes J; Forrester W; Hoffman GR; Dolmetsch R; Kaykas A
Nat Med; 2018 Jul; 24(7):939-946. PubMed ID: 29892062
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of Mdm2 and Mdm4 enhances viral gene expression during adenovirus infection.
Yang H; Zheng Z; Zhao LY; Li Q; Liao D
Cell Cycle; 2012 Feb; 11(3):582-93. PubMed ID: 22262167
[TBL] [Abstract][Full Text] [Related]
8. CRISPR deactivation in mammalian cells using photocleavable guide RNAs.
Zou RS; Liu Y; Ha T
STAR Protoc; 2021 Dec; 2(4):100909. PubMed ID: 34746867
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9 can mediate high-efficiency off-target mutations in mice in vivo.
Aryal NK; Wasylishen AR; Lozano G
Cell Death Dis; 2018 Oct; 9(11):1099. PubMed ID: 30368519
[No Abstract] [Full Text] [Related]
10. Inconclusive studies on possible CRISPR-Cas off-targets should moderate expectations about enzymes that have evolved to be non-specific.
Chakraborty S
J Biosci; 2018 Jun; 43(2):225-228. PubMed ID: 29872009
[No Abstract] [Full Text] [Related]
11. KDM6A-Mediated Expression of the Long Noncoding RNA DINO Causes TP53 Tumor Suppressor Stabilization in Human Papillomavirus 16 E7-Expressing Cells.
Sharma S; Munger K
J Virol; 2020 Jun; 94(12):. PubMed ID: 32269126
[TBL] [Abstract][Full Text] [Related]
12. FKBP25, a novel regulator of the p53 pathway, induces the degradation of MDM2 and activation of p53.
Ochocka AM; Kampanis P; Nicol S; Allende-Vega N; Cox M; Marcar L; Milne D; Fuller-Pace F; Meek D
FEBS Lett; 2009 Feb; 583(4):621-6. PubMed ID: 19166840
[TBL] [Abstract][Full Text] [Related]
13. Genome-scale CRISPR screens are efficient in non-homologous end-joining deficient cells.
Ferreira da Silva J; Salic S; Wiedner M; Datlinger P; Essletzbichler P; Hanzl A; Superti-Furga G; Bock C; Winter G; Loizou JI
Sci Rep; 2019 Oct; 9(1):15751. PubMed ID: 31673055
[TBL] [Abstract][Full Text] [Related]
14. Application of prime editing system to introduce TP53 R248Q hotspot mutation in acute lymphoblastic leukemia cell line.
Nguyen T; Aida T; Iijima-Yamashita Y; Tamai M; Nagamachi A; Kagami K; Komatsu C; Kasai S; Akahane K; Goi K; Inaba T; Sanada M; Inukai T
Cancer Sci; 2024 Jun; 115(6):1924-1935. PubMed ID: 38549229
[TBL] [Abstract][Full Text] [Related]
15. Shooting the messenger: RNA-targetting CRISPR-Cas systems.
Zhu Y; Klompe SE; Vlot M; van der Oost J; Staals RHJ
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29748239
[TBL] [Abstract][Full Text] [Related]
16. In vivo analysis of renal epithelial cells in zebrafish.
Li Y; Xu W; Jerman S; Sun Z
Methods Cell Biol; 2019; 154():163-181. PubMed ID: 31493817
[TBL] [Abstract][Full Text] [Related]
17. Validation of MdmX as a therapeutic target for reactivating p53 in tumors.
Garcia D; Warr MR; Martins CP; Brown Swigart L; Passegué E; Evan GI
Genes Dev; 2011 Aug; 25(16):1746-57. PubMed ID: 21852537
[TBL] [Abstract][Full Text] [Related]
18. CRISPR-Cas systems: ushering in the new genome editing era.
Perez Rojo F; Nyman RKM; Johnson AAT; Navarro MP; Ryan MH; Erskine W; Kaur P
Bioengineered; 2018; 9(1):214-221. PubMed ID: 29968520
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations.
Cullot G; Boutin J; Toutain J; Prat F; Pennamen P; Rooryck C; Teichmann M; Rousseau E; Lamrissi-Garcia I; Guyonnet-Duperat V; Bibeyran A; Lalanne M; Prouzet-Mauléon V; Turcq B; Ged C; Blouin JM; Richard E; Dabernat S; Moreau-Gaudry F; Bedel A
Nat Commun; 2019 Mar; 10(1):1136. PubMed ID: 30850590
[TBL] [Abstract][Full Text] [Related]
20. MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53.
Klein AM; Biderman L; Tong D; Alaghebandan B; Plumber SA; Mueller HS; van Vlimmeren A; Katz C; Prives C
Proc Natl Acad Sci U S A; 2021 Nov; 118(44):. PubMed ID: 34716260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
